Cullinan Therapeutics
June 22, 2026
Theater 3
Type: Company Presentation
Focus Area:
Multiple Therapeutics
Cullinan Therapeutics, Inc. is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients.
We believe in Science That Moves: working at a pace that boldly moves science, treatments, and people forward. Our precise, disciplined approach results in the advancement of programs that maximize therapeutic potential for patients. Taking definitive action with speed and agility is embedded in who we are. We apply our deep understanding of the immune system and leadership in T cell engagers to pursue new treatment options for patients in need.
Company HQ City:
Cambridge
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
CLN-978 (lead wholly owned product in development)
CEO
Nadim Ahmed
Development Phase of Lead Product
Phase I
Exchange
Nasdaq
Ticker
CGEM
When you expect your next catalyst update?
June 2026
What is your next catalyst (value inflection) update?
In Q2 2026, the Company plans to deliver the first company-sponsored data for a potential best-in-class CD19 T cell engager in autoimmune diseases. The initial data in systemic lupus erythematosus and rheumatoid arthritis will focus on safety and B cell depletion, other biomarker data, and preliminary clinical activity data.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}